Loading...
01/11 11:31
Loading...
Abbott Laboratories (ABT) is set to release its FY2025Q3 earnings performance on 10/15 04:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 11.42B and an earnings per share (EPS) of 1.30 for the FY2025Q3. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Abbott Laboratories is expected to outperform consensus estimates due to strong growth in its Medical Devices segment and operational efficiencies.
Fact Data Analysis
Abbott’s Navitor TAVI system received CE Mark approval in Europe for low/intermediate-risk patients (Aug 2025), significantly expanding its addressable market. This aligns with strong demand in structural heart devices, supporting double-digit Medical Devices sales growth.
Competitive advancements in diabetes care (e.g., glucose-ketone dual sensor) complicate DexCom’s market share (per Oppenheimer), positioning Abbott to capture incremental demand.
Risks:
Rationale: Consensus expectations are modest (flat revenue/EPS revisions), but Fact Data suggests underappreciated upside in Medical Devices and margins. The stock’s moderate outperformance vs. S&P 500 (+7% vs. +6.8%) leaves room for further gains on Beat confirmation.
The earnings call summary and Q&A indicate strong growth prospects in diabetes care and heart failure, with positive developments in new product launches like the dual-analyte sensor and AVEIR pacemaker. Despite headwinds in diagnostics and China's market, the company's strategic focus on innovation and expansion in high-growth segments like Structural Heart and EP suggest a positive outlook. However, the lack of detailed guidance on CMS coverage and tariff impacts introduces some uncertainty, but overall, the sentiment leans towards a positive stock price movement.
Abbott's earnings call highlights strong financial performance, with high single-digit sales growth and double-digit EPS growth. The company is optimistic about future growth, driven by new product developments and market opportunities. Despite some headwinds, such as reduced COVID testing sales and challenges in China, Abbott is strategically positioned for continued success. The positive sentiment from analysts during the Q&A session reinforces this outlook, particularly in diabetes, CRM, and biosimilars. Overall, the sentiment leans positive, with potential for stock price appreciation in the near term.
The earnings call presents a mixed picture. Strong financial metrics, such as EPS growth and gross margin expansion, are positive. However, the lack of a share repurchase program and challenges like tariffs and competitive pressures weigh negatively. The Q&A reveals management's optimism about new product launches but also highlights uncertainties, particularly around tariffs and vague M&A plans. The overall sentiment is balanced by both positive growth indicators and potential risks, leading to a neutral prediction for stock price movement.
The earnings call presents a mixed picture: strong financial metrics and positive product developments are offset by concerns over tariffs and regulatory challenges. While there are no immediate negative catalysts, such as a secondary offering or guidance cut, the lack of a shareholder return plan and unclear management responses in the Q&A create uncertainty. Given the absence of a market cap, the overall sentiment is neutral, with potential for slight positive or negative fluctuations within the 2% range.
Abbott Laboratories (ABT) is scheduled to release its FY2025Q3 earnings report onOct 15, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
Analysts' consensus predicts 11.42B in revenue and an EPS of 1.30 for Abbott Laboratories's FY2025Q3.
Intellectia's exclusive AI algorithms forecast a Beat forAbbott Laboratories's FY2025Q3 earnings, with a prediction date of Oct 15, 2025. Abbott Laboratories Abbott Laboratories is expected to outperform consensus estimates due to strong growth in its Medical Devices segment and operational efficiencies.
Leverage Intellectia's AI forecast to position trades ahead of theOct 15, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
Each prediction includes a detailed rationale, key indicator forecasts, and scenario probabilities to guide your trades. For a *Beat*, consider buying call options or shares; for a *Miss*, explore puts or hedging strategies. The prediction card provides actionable suggestions, like specific option strikes or hedging tips, tailored to your risk tolerance. Trade smart and turn insights into profits!
